These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34453497)

  • 1. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
    Ben Hassine K; Nava T; Théoret Y; Nath CE; Daali Y; Kassir N; Lewis V; Bredius RGM; Shaw PJ; Bittencourt H; Krajinovic M; Uppugunduri CRS; Ansari M
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1043-1056. PubMed ID: 34453497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
    Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
    Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
    Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
    Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.
    Sun Y; Huang J; Hao C; Li Z; Liang W; Zhang W; Chen B; Yang W; Hu J
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):293-308. PubMed ID: 31834435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.
    Nava T; Rezgui MA; Uppugunduri CRS; Curtis PH; Théoret Y; Duval M; Daudt LE; Ansari M; Krajinovic M; Bittencourt H
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1918-1924. PubMed ID: 28807770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
    Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
    Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
    Gaziev J; Nguyen L; Puozzo C; Mozzi AF; Casella M; Perrone Donnorso M; Gravina P; Sodani P; Marziali M; Isgrò A; Simone MD; Andreani M; Formosa A; Testi M; Federici G; Bernardini S; Lucarelli G
    Blood; 2010 Jun; 115(22):4597-604. PubMed ID: 20237319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
    Clemmons AB; Evans S; DeRemer DL; Awan FT
    J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
    Kim SD; Lee JH; Hur EH; Lee JH; Kim DY; Lim SN; Choi Y; Lim HS; Bae KS; Noh GJ; Yun SC; Han SB; Lee KH
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1222-30. PubMed ID: 21215809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
    Ansari M; Lauzon-Joset JF; Vachon MF; Duval M; Théoret Y; Champagne MA; Krajinovic M
    Bone Marrow Transplant; 2010 Feb; 45(2):261-7. PubMed ID: 19584821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
    de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
    J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing algorithm revisit for busulfan following IV infusion.
    Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
    Kikuchi T; Mori T; Ohwada C; Onoda M; Shimizu H; Yokoyama H; Onizuka M; Koda Y; Kato J; Takeda Y; Hino Y; Mishina T; Sakaida E; Shono K; Nagao Y; Yokota A; Matsumoto K; Morita K; Okamoto S;
    Int J Hematol; 2021 Jan; 113(1):128-133. PubMed ID: 32886279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.
    Wu X; Xie H; Lin W; Yang T; Li N; Lin S; Yuan X; Ren J; Li X; Huang X
    Clin Exp Pharmacol Physiol; 2017 May; 44(5):529-538. PubMed ID: 28135768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients.
    Ansari M; Huezo-Diaz P; Rezgui MA; Marktel S; Duval M; Bittencourt H; Cappelli B; Krajinovic M
    Bone Marrow Transplant; 2016 Mar; 51(3):377-83. PubMed ID: 26691424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.